Literature DB >> 29333942

SIX1 and DACH1 influence the proliferation and apoptosis of hepatocellular carcinoma through regulating p53.

Qi Cheng1, Deng Ning2, Jin Chen1, Xue Li3, Xiao-Ping Chen1, Li Jiang2.   

Abstract

ABSTRACTS This research aimed to explore effects of SIX1 and DACH1 on hepatocellular carcinoma (HCC) cell proliferation, apoptosis and cell cycle. Fifty paired hepatocellular carcinoma tissues were screened for differentially expressed genes. SIX1 and DACH1 expressions were subjected to qRT-PCR and western blot in tumor tissues and cells. The knockdown efficiency of siRNAs and transfection efficiency of cDNAs and siRNAs were validated by qRT-PCR and western blot as well. Then colony formation assay and flow cytometry were applied to observe cell proliferation, cell apoptosis and cell cycle changes. Immunofluorescence co-localization and immunoprecipitation were used to analyze the interaction between proteins which was quantified using western blot. Effects of SIX1 and DACH1 on tumor growth and their expressions in tumors were confirmed in vitro in nude mice model. Results of these experiments showed that SIX1 was overexpressed while DACH1 was suppressed in HCC tissues and cells. The suppression of SIX1 and overexpression of DACH1 not only inhibited cell proliferation, but also induced cell apoptosis and arrested cell cycle in G2/M phase compared with control group. Results of immunofluorescence co-localization suggested that SIX1, p53 and DACH1 were significantly overlapped. Immunoprecipitation showed that DACH1 (marked with Flag tag) could pull down p53 and SIX1, but SIX1 (marked with His tag) could only pull down DACH1, which indicated that an indirect regulation between SIX1 and p53. Validated with western blot afterwards, DACH1 overexpression suppressed tumorigenesis in vivo by up-regulating p53 expression while SIX1 overexpression accelerated tumor growth by down-regulating p53 expression. Therefore, the decrease of SIX1 facilitated the expression of DACH1, thus activated the expression of p53 and suppressed the progression of HCC both in vitro and in vivo.

Entities:  

Keywords:  DACH1; SIX1; apoptosis; hepatocellular carcinoma; p53; proliferation

Mesh:

Substances:

Year:  2018        PMID: 29333942      PMCID: PMC5915043          DOI: 10.1080/15384047.2018.1423920

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  21 in total

1.  DACH1 regulates cell cycle progression of myeloid cells through the control of cyclin D, Cdk 4/6 and p21Cip1.

Authors:  Jae-Woong Lee; Hyeng-Soo Kim; Seonggon Kim; Junmo Hwang; Young Hun Kim; Ga Young Lim; Wern-Joo Sohn; Suk-Ran Yoon; Jae-Young Kim; Tae Sung Park; Kwon Moo Park; Zae Young Ryoo; Sanggyu Lee
Journal:  Biochem Biophys Res Commun       Date:  2012-03-03       Impact factor: 3.575

2.  Six1 promotes colorectal cancer growth and metastasis by stimulating angiogenesis and recruiting tumor-associated macrophages.

Authors:  Hanwen Xu; Yu Zhang; Maria M Peña; Lucia Pirisi; Kim E Creek
Journal:  Carcinogenesis       Date:  2017-03-01       Impact factor: 4.944

3.  CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway.

Authors:  Qichao Huang; Jibin Li; Jinliang Xing; Weiwei Li; Hongwei Li; Xia Ke; Jing Zhang; Tingting Ren; Yukui Shang; Hushan Yang; Jianli Jiang; Zhinan Chen
Journal:  J Hepatol       Date:  2014-05-05       Impact factor: 25.083

4.  Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation.

Authors:  Kongming Wu; Ke Chen; Chenguang Wang; Xuanmao Jiao; Liping Wang; Jie Zhou; Jing Wang; Zhiping Li; Sankar Addya; Poul H Sorensen; Michael P Lisanti; Andrew Quong; Adam Ertel; Richard G Pestell
Journal:  Cancer Res       Date:  2013-12-12       Impact factor: 12.701

Review 5.  The DACH/EYA/SIX gene network and its role in tumor initiation and progression.

Authors:  Yu Liu; Na Han; Si Zhou; Rong Zhou; Xun Yuan; Hanxiao Xu; Cuntai Zhang; Tiejun Yin; Kongming Wu
Journal:  Int J Cancer       Date:  2015-06-12       Impact factor: 7.396

6.  Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth.

Authors:  Z-J Ren; X-Y Nong; Y-R Lv; H-H Sun; P-P An; F Wang; X Li; M Liu; H Tang
Journal:  Cell Death Dis       Date:  2014-08-21       Impact factor: 8.469

7.  Increased expression of Six1 correlates with progression and prognosis of prostate cancer.

Authors:  Jun Zeng; Rong Shi; Cui-Xia Cai; Xin-Rui Liu; Yan-Bin Song; Min Wei; Wen-Li Ma
Journal:  Cancer Cell Int       Date:  2015-06-20       Impact factor: 5.722

8.  DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling.

Authors:  Na Han; Xun Yuan; Hua Wu; Hanxiao Xu; Qian Chu; Mingzhou Guo; Shiying Yu; Yuan Chen; Kongming Wu
Journal:  Oncotarget       Date:  2015-03-20

9.  DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells.

Authors:  Qian Chu; Na Han; Xun Yuan; Xin Nie; Hua Wu; Yu Chen; Mingzhou Guo; Shiying Yu; Kongming Wu
Journal:  J Hematol Oncol       Date:  2014-10-17       Impact factor: 17.388

10.  Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling.

Authors:  Liang Wu; James G Herman; Malcolm V Brock; Kongming Wu; Gaoping Mao; Wenji Yan; Yan Nie; Hao Liang; Qimin Zhan; Wen Li; Mingzhou Guo
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

View more
  8 in total

Review 1.  SIX3 function in cancer: progression and comprehensive analysis.

Authors:  Tian-Liang Ma; Peng Zhu; Jing-Xian Chen; Yi-He Hu; Jie Xie
Journal:  Cancer Gene Ther       Date:  2022-06-28       Impact factor: 5.987

2.  Analysis of Key Genes Regulating the Warburg Effect in Patients with Gastrointestinal Cancers and Selective Inhibition of This Metabolic Pathway in Liver Cancer Cells.

Authors:  Xinyue Zhang; Jinan Guo; Parham Jabbarzadeh Kaboli; Qijie Zhao; Shixin Xiang; Jing Shen; Yueshui Zhao; Fukuan Du; Xu Wu; Mingxing Li; Huijiao Ji; Xiao Yang; Zhangang Xiao; Qinglian Wen
Journal:  Onco Targets Ther       Date:  2020-07-27       Impact factor: 4.147

3.  Sine oculis homeobox 1 promotes proliferation and migration of human colorectal cancer cells through activation of Wnt/β-catenin signaling.

Authors:  Wenxin Song; Jian Ma; Bingbing Lei; Xin Yuan; Binfeng Cheng; Haijie Yang; Mian Wang; Zhiwei Feng; Lei Wang
Journal:  Cancer Sci       Date:  2019-01-28       Impact factor: 6.716

4.  Protein phosphatase 2 regulatory subunit B''Alpha silencing inhibits tumor cell proliferation in liver cancer.

Authors:  Huijuan Chen; Jing Xu; Peixiao Wang; Qingming Shu; Lihong Huang; Jing Guo; Xuyi Zhang; Hongying Zhang; Ying Wang; Zhongyang Shen; Xinguo Chen; Qing Zhang
Journal:  Cancer Med       Date:  2019-10-24       Impact factor: 4.452

5.  Identification of immune infiltration-related genes as prognostic indicators for hepatocellular carcinoma.

Authors:  Kunfu Dai; Chao Liu; Ge Guan; Jinzhen Cai; Liqun Wu
Journal:  BMC Cancer       Date:  2022-05-05       Impact factor: 4.638

6.  Both a hypoxia-inducible EYA3 and a histone acetyltransferase p300 function as coactivators of SIX5 to mediate tumorigenesis and cancer progression.

Authors:  Chunmei Yang; Hong Liu
Journal:  Ann Transl Med       Date:  2022-07

7.  Organoid modelling identifies that DACH1 functions as a tumour promoter in colorectal cancer by modulating BMP signalling.

Authors:  Xiang Hu; Long Zhang; Yaqi Li; Xiaoji Ma; Weixing Dai; Xiaoxue Gao; Xinxin Rao; Guoxiang Fu; Renjie Wang; Mengxue Pan; Qiang Guo; Xiaoya Xu; Yi Zhou; Jianjun Gao; Zhen Zhang; Sanjun Cai; Junjie Peng; Guoqiang Hua
Journal:  EBioMedicine       Date:  2020-06-06       Impact factor: 8.143

8.  O-GlcNAcylation of SIX1 enhances its stability and promotes Hepatocellular Carcinoma Proliferation.

Authors:  Yi Chu; Mingzuo Jiang; Nan Wu; Bing Xu; Wenjiao Li; Haiming Liu; Song Su; Yanting Shi; Hao Liu; Xiaoliang Gao; Xin Fu; Di Chen; Xiaowei Li; Weijie Wang; Jie Liang; Yongzhan Nie; Daiming Fan
Journal:  Theranostics       Date:  2020-08-02       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.